China Biologics Market Size & Outlook, 2024-2030
China biologics market, 2018-2030 (US$M)
Related Markets
China biologics market highlights
- The China biologics market generated a revenue of USD 23.3 million in 2024 and is expected to reach USD 43.9 million by 2030.
- The China market is expected to grow at a CAGR of 11.1% from 2025 to 2030.
- In terms of segment, microbial was the largest revenue generating biologics source in 2024.
- Others Biologics Source is the most lucrative biologics source segment registering the fastest growth during the forecast period.
Biologics market data book summary
| Market revenue in 2024 | USD 23.3 million |
| Market revenue in 2030 | USD 43.9 million |
| Growth rate | 11.1% (CAGR from 2024 to 2030) |
| Largest segment | Microbial |
| Fastest growing segment | Others Biologics Source |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Microbial, Mammalian, Others Biologics Source |
| Key market players worldwide | Samsung BioLogics, Amgen Inc, Novo Nordisk A/S ADR, AbbVie Inc, Sanofi SA, Johnson & Johnson, Celltrion Healthcare, Bristol-Myers Squibb Co, Eli Lilly and Co, Roche Holding AG ADR |
Other key industry trends
- In terms of revenue, China accounted for 4.1% of the global biologics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan biologics market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 35.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biologics Market Scope
Biologics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China biologics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics market will help companies and investors design strategic landscapes.
Microbial was the largest segment with a revenue share of 58.37% in 2024. Horizon Databook has segmented the China biologics market based on microbial, mammalian, others biologics source covering the revenue growth of each sub-segment from 2018 to 2030.
One of the key drivers responsible for the emergence of the Chinese biologic market is the continuous proliferation of biologic developing plants in the country. In the current scenario, China has received gradual recognition as a commercially attractive market for biologics sales.
Continuous efforts by the regulators, policymakers, and the pharmaceutical industry jointly to address both the affordability and availability of biologics, especially mAbs, are anticipated to expand the Chinese market size of biologics in the coming years.
In December 2015, AstraZeneca undertook several strategic initiatives for acceleration of innovative biologics and targeted medicines delivery to patients in China. Strategic initiatives included a partnership with WuXi AppTec for the production of innovative biologics and investment in building a manufacturing site in Wuxi City.
Reasons to subscribe to China biologics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China biologics market databook
-
Our clientele includes a mix of biologics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China biologics market , including forecasts for subscribers. This country databook contains high-level insights into China biologics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China Biologics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
